{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:28:11Z","timestamp":1793327291275,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Plasma cell\u2013rich rejection (PCCR), also known as \u201cplasma cell hepatitis\u201d or \u201cde novo autoimmune hepatitis,\u201d is a cause of allograft dysfunction occurring post\u2013liver transplantation (LT). Patients often develop allograft failure and may require repeat LT. PCRR may fall within the spectrum of different histologies associated with antibody-mediated rejection (AMR), which is associated with donor-specific antibodies (DSAs) and positive complement component C4 (C4d) immunostaining. We sought to analyze the histologic and clinical outcomes of patients having biopsy-proven PCRR as well as to examine its C4d staining and DSA profiles.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We identified patients having PCRR between 2000 and 2020 using the electronic pathology database at our institution. We included patients who underwent at least one follow-up liver biopsy after establishing the PCRR diagnosis to assess future histologic progression and outcomes. Mean fluorescence intensity for at least one single DSA of 2,000 or higher was considered positive. Histologic diagnosis of PCRR was independently made by an experienced liver pathologist.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 35 patients were included in the study. Hepatitis C virus was the most common etiology for LT (59.5%). Mean \u00b1 SD age at LT was 49.0 \u00b1 12.7 years. Forty percent of patients developed PCRR within 2 years of LT. Most patients (68.5%) had negative outcomes, with progression from PCRR to cirrhosis or chronic ductopenic rejection (CDR). Patients who had hepatitis C virus were more likely to develop cirrhosis rather than CDR following the PCRR diagnosis (P = .01). Twenty-three (65.7%) patients had at least one prior episode of T-cell\u2013mediated rejection before being diagnosed with PCRR. DSAs were positive in 16 of 19 patients assessed, and C4d immunostaining was positive in 9 of 10 patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Development of PCRR negatively affects liver allograft outcomes and patient survival after LT. The presence of DSA and C4d in PCRR patients supports it to be within the histologic spectrum of AMR.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad004","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T13:42:16Z","timestamp":1678282936000},"page":"49-57","source":"Crossref","is-referenced-by-count":17,"title":["Histologic and Clinical Outcomes of Patients Developing Post\u2013Liver Transplant Plasma Cell\u2013Rich Rejection"],"prefix":"10.1093","volume":"160","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8595-1838","authenticated-orcid":false,"given":"Nazli Begum","family":"Ozturk","sequence":"first","affiliation":[{"name":"Division of Liver Diseases and Recanati\/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas D","family":"Schiano","sequence":"additional","affiliation":[{"name":"Division of Liver Diseases and Recanati\/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Fiel","sequence":"additional","affiliation":[{"name":"Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai , New York, NY , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"2023070513454138400_CIT0001","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/lt.25375","article-title":"Recurrent and de novo autoimmune hepatitis","volume":"25","author":"Stirnimann","year":"2019","journal-title":"Liver Transplant."},{"key":"2023070513454138400_CIT0002","doi-asserted-by":"crossref","first-page":"e13978","DOI":"10.1111\/petr.13978","article-title":"A two decade long study of disease progression of de novo and recurrent autoimmune hepatitis in the pediatric population","volume":"25","author":"Hadley","year":"2021","journal-title":"Pediatr Transplant."},{"key":"2023070513454138400_CIT0003","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1478-3231.2012.02832.x","article-title":"Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation","volume":"32","author":"Montano-Loza","year":"2012","journal-title":"Liver Int."},{"key":"2023070513454138400_CIT0004","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1111\/ajt.13909","article-title":"2016 Comprehensive update of the Banff Working Group on liver allograft pathology: introduction of antibody-mediated rejection","volume":"16","author":"Demetris","year":"2016","journal-title":"Am J Transplant."},{"key":"2023070513454138400_CIT0005","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jhep.2021.07.027","article-title":"Antibody-mediated rejection of the liver allograft: an update and a clinico-pathological perspective","volume":"75","author":"Lee","year":"2021","journal-title":"J Hepatol."},{"key":"2023070513454138400_CIT0006","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/lt.21447","article-title":"Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus","volume":"14","author":"Fiel","year":"2008","journal-title":"Liver Transplant."},{"key":"2023070513454138400_CIT0007","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/ajt.12667","article-title":"The role of donor-specific HLA alloantibodies in liver transplantation: DSA in liver transplantation","volume":"14","author":"O\u2019Leary","year":"2014","journal-title":"Am J Transplant."},{"key":"2023070513454138400_CIT0008","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/MOT.0000000000000194","article-title":"ABO-compatible liver allograft antibody-mediated rejection: an update","volume":"20","author":"Demetris","year":"2015","journal-title":"Curr Opin Organ Transplant."},{"key":"2023070513454138400_CIT0009","first-page":"369","article-title":"Recurrent idiopathic liver allograft failure","volume":"152","author":"Schiano","year":"2019","journal-title":"Am J Clin Pathol."},{"key":"2023070513454138400_CIT0010","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2011.03.005","article-title":"What is the long-term outcome of the liver allograft?","volume":"55","author":"H\u00fcbscher","year":"2011","journal-title":"J Hepatol."},{"key":"2023070513454138400_CIT0011","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/lt.21518","article-title":"Plasma cell hepatitis in liver allografts: variant of rejection or autoimmune hepatitis?","volume":"14","author":"Demetris","year":"2008","journal-title":"Liver Transpl."},{"key":"2023070513454138400_CIT0012","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/hep.30281","article-title":"Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients: hepatology","volume":"69","author":"Jucaud","year":"2019","journal-title":"Hepatology."},{"key":"2023070513454138400_CIT0013","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1111\/ajt.12212","article-title":"De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients: de novo DSA in liver transplantation","volume":"13","author":"Kaneku","year":"2013","journal-title":"Am J Transplant."},{"key":"2023070513454138400_CIT0014","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.TP.0000132328.33460.43","article-title":"Outcome and risk factors of de novo autoimmune hepatitis in living-donor liver transplantation","volume":"78","author":"Miyagawa-Hayashino","year":"2004","journal-title":"Transplantation."},{"key":"2023070513454138400_CIT0015","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1111\/j.1600-6143.2006.01717.x","article-title":"Rejection and steroid dependence: unique risk factors in the development of pediatric posttransplant de novo autoimmune hepatitis","volume":"7","author":"Venick","year":"2007","journal-title":"Am J Transplant."},{"key":"2023070513454138400_CIT0016","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00007890-200201150-00015","article-title":"Late cellular rejection in paediatric liver transplantation: aetiology and outcome","volume":"73","author":"D\u02bcantiga","year":"2002","journal-title":"Transplantation."},{"key":"2023070513454138400_CIT0017","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1046\/j.1399-0012.2003.00139.x","article-title":"The incidence and significance of late acute cellular rejection (&gt;1000 days) after liver transplantation","volume":"18","author":"Florman","year":"2004","journal-title":"Clin Transplant."},{"key":"2023070513454138400_CIT0018","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/lt.21949","article-title":"Plasma cell hepatitis in hepatitis C virus patients post-liver transplantation: case-control study showing poor outcome and predictive features in the liver explant: post-liver transplant plasma cell hepatitis","volume":"15","author":"Ward","year":"2009","journal-title":"Liver Transplant."},{"key":"2023070513454138400_CIT0019","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/01.tp.0000269609.08495.45","article-title":"Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin","volume":"84","author":"Stanca","year":"2007","journal-title":"Transplantation."},{"key":"2023070513454138400_CIT0020","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/ndt\/gfm678","article-title":"Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts","volume":"23","author":"Weclawiack","year":"2007","journal-title":"Nephrol Dial Transplant."},{"key":"2023070513454138400_CIT0021","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1097\/00007890-199504150-00030","article-title":"Interferon-\u03b1-induced acute renal allograft rejection.","volume":"59","author":"Magnone","year":"1995","journal-title":"Transplantation"},{"key":"2023070513454138400_CIT0022","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/gut.2006.092064","article-title":"High incidence of allograft dysfunction in liver transplanted patients treated with pegylated-interferon alpha-2b and ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis?","volume":"56","author":"Berardi","year":"2007","journal-title":"Gut."},{"key":"2023070513454138400_CIT0023","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1111\/ajt.15053","article-title":"Immune-mediated graft dysfunction in liver transplant recipients with hepatitis C virus treated with direct-acting antiviral therapy","volume":"18","author":"Chan","year":"2018","journal-title":"Am J Transplant."},{"key":"2023070513454138400_CIT0024","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1053\/j.gastro.2012.01.030","article-title":"Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon","volume":"142","author":"Levitsky","year":"2012","journal-title":"Gastroenterology"},{"key":"2023070513454138400_CIT0025","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.transproceed.2012.07.069","article-title":"Liver transplantation due to fulminant hepatic failure","volume":"44","author":"G\u00f3mez Cabeza de Vaca","year":"2012","journal-title":"Transplant Proc."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/1\/49\/50822420\/aqad004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/1\/49\/50822420\/aqad004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T19:17:43Z","timestamp":1688584663000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/160\/1\/49\/7072565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,8]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad004","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,3,8]]}}}